MicroRNAs, Stem Cells in Bipolar Disorder, and Lithium Therapeutic Approach

Int J Mol Sci. 2022 Sep 10;23(18):10489. doi: 10.3390/ijms231810489.

Abstract

Bipolar disorder (BD) is a severe, chronic, and disabling neuropsychiatric disorder characterized by recurrent mood disturbances (mania/hypomania and depression, with or without mixed features) and a constellation of cognitive, psychomotor, autonomic, and endocrine abnormalities. The etiology of BD is multifactorial, including both biological and epigenetic factors. Recently, microRNAs (miRNAs), a class of epigenetic regulators of gene expression playing a central role in brain development and plasticity, have been related to several neuropsychiatric disorders, including BD. Moreover, an alteration in the number/distribution and differentiation potential of neural stem cells has also been described, significantly affecting brain homeostasis and neuroplasticity. This review aimed to evaluate the most reliable scientific evidence on miRNAs as biomarkers for the diagnosis of BD and assess their implications in response to mood stabilizers, such as lithium. Neural stem cell distribution, regulation, and dysfunction in the etiology of BD are also dissected.

Keywords: bipolar disorder (BD); lithium; microRNA; molecular mechanisms; neural stem cells; stem cells.

Publication types

  • Review

MeSH terms

  • Antimanic Agents / therapeutic use
  • Bipolar Disorder* / diagnosis
  • Bipolar Disorder* / drug therapy
  • Bipolar Disorder* / genetics
  • Humans
  • Lithium / pharmacology
  • Lithium / therapeutic use
  • MicroRNAs* / genetics
  • MicroRNAs* / therapeutic use
  • Stem Cells / metabolism

Substances

  • Antimanic Agents
  • MicroRNAs
  • Lithium

Grants and funding

This research received no external funding.